UM Guidelines

	Clinical Indications removed Genetic Counseling requirement:
	Y chromosome microdeletion analysis is necessary for ALL of the following : Male age 18 years or older. Individuals assigned male at birth, including transgender women, prior to gender-affirming surgery. Infertility evaluation completed, including semen analysis, hormonal evaluation, ultrasound evaluation or any other pertinent evaluation, physical examination do not reveal source of male infertility and further testing is supported. Karyotype testing completed and negative for chromosomal abnormalities associated with infertility. Evidence Summary Y chromosome microdeletions are among the most common identifiable genetic causes of severe male factor infertility and represent the second most common genetic cause of spermatogenic failure after Klinefelter syndrome (47,XXY). Deletions occur within the azoospermia factor (AZF) region on the long arm of the Y chromosome and result in impaired spermatogenesis through loss of genes critical for sperm production. Clinical manifestations range from severe oligospermia to complete nonobstructive azoospermia. Most affected individuals are otherwise healthy and asymptomatic, although small testicular volume may be present. Semen analysis typically demonstrates azoospermia or severe oligospermia. The AZF region contains three major subregions: AZFa AZFb AZFc These deletions demonstrate genotype-phenotype correlations: Complete AZFa deletions are commonly associated with Sertoli cell-only syndrome and absence of sperm production. Complete AZFb deletions are typically associated with severe spermatogenic arrest and absence of retrievable sperm. AZFc deletions are the most common and show variable phenotypes ranging from severe oligospermia to azoospermia; some affected men may have retrievable sperm and may successfully achieve pregnancy through assisted reproductive technologies. Because Y chromosome microdeletions are Y-linked, male offspring conceived through intracytoplasmic sperm injection (ICSI) will inherit the deletion and are expected to be at risk for infertility. Most Y chromosome microdeletions arise de novo because affected men are frequently infertile. Testing is typically performed using peripheral blood DNA with multiplex PCR-based techniques designed to identify deletions within the AZF regions. Clinical Utility Y chromosome microdeletion testing provides clinically actionable information in the evaluation of male infertility. The test may: Establish a genetic diagnosis for severe oligospermia or nonobstructive azoospermia. Provide prognostic information regarding the likelihood of successful sperm retrieval. Guide decisions regarding microsurgical testicular sperm extraction (micro-TESE). Assist reproductive counseling regarding ICSI. Inform counseling regarding transmission of infertility risk to male offspring. Avoid unnecessary surgical interventions in patients unlikely to benefit from sperm retrieval procedures. The strongest prognostic utility occurs when evaluating men for assisted reproductive technologies. Men with complete AZFa or AZFb deletions generally have an extremely poor likelihood of sperm retrieval, whereas men with AZFc deletions may have successful sperm retrieval and subsequent reproductive options. Evidence Supporting Testing A large retrospective study and meta-analysis involving more than 10,000 men evaluated for infertility reported an overall Y chromosome microdeletion prevalence of approximately 3.5%, with substantially higher frequencies among men with nonobstructive azoospermia and severe oligospermia. Numerous studies have demonstrated that identification of specific AZF deletions affects reproductive planning and procedural decision-making. The findings influence: Selection for sperm retrieval procedures Counseling regarding expected outcomes Utilization of assisted reproductive technologies Genetic counseling for offspring Current AUA/ASRM Male Infertility Guidelines (2020, amended 2024) recommend Y chromosome microdeletion testing in men with azoospermia or severe oligospermia associated with primary testicular failure because results may establish an underlying genetic diagnosis, provide prognostic information regarding sperm retrieval success, guide assisted reproductive planning, and support counseling regarding transmission of infertility to male offspring. The guideline recognizes Y chromosome microdeletion analysis as a standard component of the genetic evaluation of severe male factor infertility. Professional Society Support Y chromosome microdeletion analysis is supported by the American Urological Association (AUA), American Society for Reproductive Medicine (ASRM), European Academy of Andrology (EAA), European Association of Urology (EAU), and other reproductive genetics experts as a clinically useful diagnostic and prognostic test for men with severe oligospermia or nonobstructive azoospermia. Results directly influence prognosis, surgical planning, assisted reproductive technology decisions, and genetic counseling. American Urological Association (AUA) The AUA and American Society for Reproductive Medicine (ASRM) Male Infertility Guideline recommends Y chromosome microdeletion testing in men with: Primary infertility Azoospermia or severe oligospermia Suspected impaired spermatogenesis The guideline recognizes the importance of YCMD testing for diagnosis, prognosis, and reproductive counseling and supports testing prior to assisted reproductive interventions. American Society for Reproductive Medicine (ASRM) ASRM recognizes Y chromosome microdeletion analysis as a standard component of the genetic evaluation of men with severe spermatogenic failure. Findings may directly affect reproductive planning and counseling of couples considering assisted reproductive technologies. European Academy of Andrology (EAA) The EAA and European Molecular Genetics Quality Network (EMQN) Best Practice Guidelines support Y chromosome microdeletion testing in males with: Nonobstructive azoospermia Severe oligospermia Suspected testicular failure The guidelines specifically note the prognostic value of AZF subtype determination. European Association of Urology (EAU) EAU infertility guidelines continue to support Y chromosome microdeletion testing in men with severe sperm production defects because results affect diagnosis, counseling, and assisted reproduction planning. Genetic Counseling Genetic counseling is strongly recommended before and after testing. Counseling should address: Inheritance patterns Potential reproductive implications Prognosis for sperm retrieval Risks to male offspring conceived through ICSI Potential limitations of testing Alternative reproductive options Pre-test and post-test counseling remain important components of comprehensive infertility care. Summary For evaluation of male infertility, particularly severe oligospermia and nonobstructive azoospermia, evidence demonstrates clinical utility through: Establishment of a genetic diagnosis Prognostic assessment for sperm retrieval Guidance for assisted reproductive technologies Avoidance of unnecessary procedures Reproductive risk counseling Y chromosome microdeletion analysis remains supported by AUA, ASRM, EAA, EAU, and fertility specialists as a clinically useful diagnostic and prognostic test in appropriately selected males with severe spermatogenic impairment. References   Krausz C, Hoefsloot L, Simoni M, Tüttelmann F; European Academy of Andrology (EAA); European Molecular Genetics Quality Network (EMQN). EAA/EMQN Best Practice Guidelines for Molecular Diagnosis of Y-Chromosomal Microdeletions: State-of-the-Art 2013. Andrology. 2014;2(1):5-19. doi:10.1111/j.2047-2927.2013.00173.x. Reaffirmed July 2021. GeneReviews®. Y Chromosome Infertility. University of Washington, Seattle. Updated periodically. Schlegel PN, Sigman M, Collura B, De Jonge CJ, Eisenberg ML, Lamb DJ, Mulhall JP, Niederberger C, Sandlow JI, Sokol RZ, Spandorfer SD, Tanrikut C, Zini A; AUA/ASRM Guideline Panel. Diagnosis and Treatment of Infertility in Men: AUA/ASRM Guideline (2020; Amended 2024). American Urological Association and American Society for Reproductive Medicine. Approved by the AUA Board of Directors July 2024. Brannigan RE, Tanrikut C. Amendment Panel. Diagnosis and Treatment of Infertility in Men: AUA/ASRM Guideline Amendment 2024. American Urological Association/American Society for Reproductive Medicine. Practice Committee of the American Society for Reproductive Medicine. Evaluation of the Azoospermic Male. Fertility and Sterility. Most recent committee opinion. Practice Committee of the American Society for Reproductive Medicine. The Clinical Utility of Genetic Testing in Male Infertility. Fertility and Sterility. European Association of Urology (EAU). EAU Guidelines on Sexual and Reproductive Health: Male Infertility. Current edition. World Health Organization. WHO Laboratory Manual for the Examination and Processing of Human Semen. 6th Edition. Simoni M, Bakker E, Krausz C. EAA Guidelines for Molecular Diagnosis of Y Chromosomal Microdeletions. International Journal of Andrology. Colaco S, Modi D. Genetics of the Human Y Chromosome and Its Association with Male Infertility. Reproductive Biology and Endocrinology. Stahl PJ, Masson P, Mielnik A, Marean MB, Schlegel PN. Outcomes of microdissection testicular sperm extraction in men with Y chromosome microdeletions. Kohn TP, Kohn JR, Owen RC, Coward RM. The Prevalence of Y-Chromosome Microdeletions in Infertile Men: A Systematic Review and Meta-analysis. Fertility and Sterility. Tüttelmann F, Ruckert C, Röpke A. Genetics of Male Infertility: Practical Clinical Approaches. Krausz C, Cioppi F. Genetic Factors of Male Infertility: From Research to Clinical Practice. American College of Medical Genetics and Genomics (ACMG). Current recommendations for genetic evaluation of male infertility. Footnotes [A] Cytogenetic evaluation may identify numerical or structural chromosomal abnormalities but generally does not detect Y chromosome microdeletions or microduplications and cannot determine whether deletions extend into the azoospermia factor (AZF) region. Therefore, karyotyping should not be considered a substitute for Y chromosome microdeletion analysis in appropriately selected males with severe spermatogenic impairment. [B] Various professional societies, including the American Urological Association (AUA), American Society for Reproductive Medicine (ASRM), European Academy of Andrology (EAA), European Association of Urology (EAU), American College of Medical Genetics and Genomics (ACMG), and other reproductive medicine organizations have published guidance supporting incorporation of genetic testing, genetic counseling, and reproductive risk assessment into the evaluation of male infertility. [C] Y chromosome microdeletion testing provides prognostic information regarding sperm retrieval. Complete AZFa and AZFb deletions are associated with an extremely low likelihood of successful sperm retrieval, whereas men with isolated AZFc deletions may have retrievable sperm and may be candidates for intracytoplasmic sperm injection (ICSI). [D] Male offspring conceived through ICSI by fathers with Y chromosome AZF deletions are expected to inherit the deletion and may be at risk for infertility. Pre-test and post-test genetic counseling should address this inheritance risk.